The Potential Impact of Maintaining a 3-Hour IV Thrombolysis Window: How Many More Patients can we Safely Treat?

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In 2008, the European Cooperative Acute Stroke Study-3 (ECASS-3) demonstrated that intravenous-tissue plasminogen activator could be safely administered for acute stroke patients presenting between 3 and 4.5 hours from symptom onset. Recently, the Food and Drug Administration rejected expansion of this time window in the United States. We sought to determine how many fewer patients would be treated by maintaining this restricted time window.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Neurol Disord Stroke

Title: Journal of neurological disorders & stroke

Publication date (Electronic): Sep 13 2013

Volume: 1

Issue: 2

Affiliations

[1 ] Department of Neurology, School of Medicine, University of Alabama at Birmingham, USA.

[2 ] Stroke Center, Birmingham Veterans Affairs Medical Center, USA.

[3 ] Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, USA.

[4 ] Health Services and Outcomes Research Center for Outcome and Effectiveness Research and Education (COERE), University of Alabama at Birmingham, USA.

[5 ] Center for Excellence in Comparative Effectiveness Research for Eliminating Disparities (CERED) Minority Health & Health Disparities Research Center (MHRC), University of Alabama at Birmingham, USA.

[6 ] School of Nursing, University of Alabama at Birmingham, USA.

Article

Mid ID: NIHMS539863

PMC ID: 3901990

PubMed ID: 24471140

SO-VID: 19c31278-344c-4a11-a22f-5271938625e0

History

Keywords: Hemorrhage,Ischemic Stroke,Safety,Thrombolysis

Data availability:

Keywords: Hemorrhage, Ischemic Stroke, Safety, Thrombolysis

Comments

Comment on this article

Cited by 3

See all cited by